Results 191 to 200 of about 66,412 (266)

Regression for Left-Truncated and Right-Censored Data: A Semiparametric Sieve Likelihood Approach. [PDF]

Stat Med
Matthews S, Nan B.
europepmc   +1 more source

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib

Clinical Pharmacology &Therapeutics, EarlyView.
Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose ...
Devasha Redhi, Mwila Mulubwa, Mmakwena M. Mmonwa, Mathew Njoroge, Liezl Krugmann, Kelly Chibale   +5 more
wiley   +1 more source

Time-Dependent Predictive Accuracy Metrics in the Context of Interval Censoring and Competing Risks. [PDF]

Biom J
Yang Z, Rizopoulos D, Newcomb LF, Erler NS.   +3 more
europepmc   +1 more source

Prediction of Acute Liver Injury Trajectory in Patients Following Acetaminophen Overdose: A Multibiomarker Machine Learning Proof‐of‐Concept Study

Clinical Pharmacology &Therapeutics, EarlyView.
Clinical translation of novel therapies can be hindered by heterogeneity‐driven sample size inflation in late‐stage trials. In acetaminophen‐induced liver injury (APAP DILI), many patients recover spontaneously, diluting investigational drug efficacy signals.
Chris Humphries, Alastair M. Kilpatrick, Kathleen M. Scullion, Rhona Aird, Lorraine Bruce, Maria Elena Candela, Tak Yung Man, Stuart J. Forbes, James W. Dear   +8 more
wiley   +1 more source

The Challenge of Time-to-Event Analysis for Multiple Events: A Guided Tour From Time-to-First-Event to Recurrent Time-to-Event Analysis. [PDF]

Biom J
Schmeller S, Erdmann A, Beyersmann J, Angermann C, Ozga AK.   +4 more
europepmc   +1 more source

Censors – At work, censors out of work

, 2014
openaire   +2 more sources

Model‐Based Analysis with Mechanistic Insights to CAR‐T‐Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin, Martin Bergstrand, Ana Ruiz‐Garcia, Simone Filosto, Rhine Shen   +4 more
wiley   +1 more source

Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction. [PDF]

Pharmacoepidemiol Drug Saf
Cars T, Gustafsson S, Chan Q, Dhalwani N, Kent ST, Briggs A, Gale CP, Gitt A, Jukema JW, Steg PG, Sundström J, James S, Hagström E, Brookhart MA.   +13 more
europepmc   +1 more source

Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation

Clinical Pharmacology &Therapeutics, EarlyView.
Despite the immunomodulatory mechanism of immune checkpoint inhibitors (ICIs), systemic glucocorticoids are commonly used in advanced non–small cell lung cancer (NSCLC). Evidence regarding their effects on ICI outcomes is inconsistent, in part due to confounding by indication and immortal time bias.
Da Eun Lee, Geunho Lim, Minoh Ko, Mari Kim, Ji Sun Chun, Borim Lee, Miso Kim, Kwangsoo Kim, Byung Kwan Choi, Jeongmin Seo, Jin Hyoung Kang, Taehoon Ko, In‐Wha Kim, Jung Mi Oh   +13 more
wiley   +1 more source

Interpreting Postdiagnosis Toenail Metal Measurements in Childhood Nephrotic Syndrome. [PDF]

Kidney Int Rep
Wang L, Li Z, Zhong L, Zheng D.
europepmc   +1 more source